ReviewCancer genomics & proteomics
Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Analyses of Clinicopathological, Molecular, and Prognostic Characteristics With Retrospective Review of 237 Endometrial Carcinoma Cases.
Review in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Peritoneal Mesonephric-Like Adenocarcinoma Arising in Endometriosis: Case Report and Review of the Literature Expanding the Spectrum of Extrauterine Mesonephric-Like Adenocarcinomas.International journal of surgical pathology · 2026Review
- Multi-institutional study of mesonephric-like adenocarcinoma: its clinicopathological characteristics and histogenetic association with ectopic endometrium.Virchows Archiv : an international journal of pathology · 2026Article
- Mesonephric-like adenocarcinoma as an unexpected histological result after fertility saving procedure for presumed adenomyosis: a case report.Frontiers in oncology · 2026Article
- Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026Review
- Case Report: Hormone receptor-positive uterine mesonephric-like adenocarcinoma.Frontiers in medicine · 2026Article
- [Clinicopathological analysis of mesonephric-like adenocarcinoma in the corpusuteri: A report of 3 cases].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Cytopathologic features of mesonephric-like adenocarcinoma in the endometrium and ovary: eight cases and literature review.Virchows Archiv : an international journal of pathology · 2025Article
- Endometrial mesonephric-like adenocarcinoma: Clinicopathologic features, treatment, and outcomes.Biomolecules & biomedicine · 2025Article
- Epidemiological and Histopathological Characterization of Endometrial Carcinoma: A Retrospective Cohort from Romania.Diagnostics (Basel, Switzerland) · 2025Article
- A Case Report to Reflect on the Origins of MMRd Mesonephric-like Ovarian Adenocarcinoma: Can It Be Defined as a Mϋllerian Neoplasm?International journal of molecular sciences · 2025Article
- Papillary and ductal patterns of mesonephric-like adenocarcinomas are often overlooked: a retrospective revaluation of over 1000 endometrial carcinomas.Histopathology · 2025Article
- Controversies in the Management of Mesonephric and Mesonephric-Like Adenocarcinomas of the Female Genital Tract.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Review
- Mesonephric-like adenocarcinoma of the uterine corpus with focal sarcomatous differentiation: A case report.Fujita medical journal · 2025Article
- Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism.Gynecologic oncology reports · 2025Article
- Immune microenvironment heterogeneity characterizes biologically distinct KRASFrontiers in immunology · 2025Article
- Mesonephric-type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2.The journal of pathology. Clinical research · 2024Article
- Uncommon Morphologic Types of Endometrial Cancer and Their Mimickers: How Much Does Molecular Classification Improve the Practice for Challenging Cases?Life (Basel, Switzerland) · 2024Review
- Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.Gynecologic oncology · 2024Article
- Article
- Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.Journal of cancer research and clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimUterine mesonephric-like adenocarcinoma (MLA) is a rare malignant tumor of the female genital tract. PATIENTS AND
methodsWe reviewed 237 endometrial carcinoma cases and investigated the clinicopathological and molecular characteristics of uterine MLA.
resultsWe found that 3.0% (7/237) of the endometrial carcinoma cases were MLAs. Compared to endometrial endometrioid carcinoma, MLA showed larger tumor size, deeper myometrial invasion, increasingly advanced-stage disease, and more frequent lymphovascular space invasion. All MLAs exhibited architectural diversity, compactly aggregated small tubules, eosinophilic intraluminal secretions, overlapped and angulated nuclei, scant cytoplasm, and presence of spindle cells. All the MLAs expressed at least two mesonephric markers. All except one MLA harbored activating Kirsten rat sarcoma viral oncogene homolog mutations. All patients with MLA developed postoperative metastases. MLA had the lowest progression-free survival rate among different histological types of endometrial carcinoma.
conclusionUterine MLA is a highly aggressive gynecological malignancy, showing unique morphological and molecular features, frequent recurrences and metastases, as well as poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.